Summary
Global Markets Direct’s, ‘Mitogen Activated Protein Kinase 3 (ERT2 or Insulin Stimulated MAP2 Kinase or Extracellular Signal Regulated Kinase 1 or MAP Kinase Isoform p44 or Microtubule Associated Protein 2 Kinase or p44 ERK1 or MAPK3 or EC 2.7.11.24) - Pipeline Review, H2 2016’, provides in depth analysis on Mitogen Activated Protein Kinase 3 (ERT2 or Insulin Stimulated MAP2 Kinase or Extracellular Signal Regulated Kinase 1 or MAP Kinase Isoform p44 or Microtubule Associated Protein 2 Kinase or p44 ERK1 or MAPK3 or EC 2.7.11.24) targeted pipeline therapeutics.
The report provides comprehensive information on the Mitogen Activated Protein Kinase 3 (ERT2 or Insulin Stimulated MAP2 Kinase or Extracellular Signal Regulated Kinase 1 or MAP Kinase Isoform p44 or Microtubule Associated Protein 2 Kinase or p44 ERK1 or MAPK3 or EC 2.7.11.24) , targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Mitogen Activated Protein Kinase 3 (ERT2 or Insulin Stimulated MAP2 Kinase or Extracellular Signal Regulated Kinase 1 or MAP Kinase Isoform p44 or Microtubule Associated Protein 2 Kinase or p44 ERK1 or MAPK3 or EC 2.7.11.24) targeted therapeutics development and features dormant and discontinued projects.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.
Note:
*Certain sections in the report may be removed or altered based on the availability and relevance of data.
*Updated report will be delivered in 48 hours of order confirmation.
Scope
- The report provides a snapshot of the global therapeutic landscape for Mitogen Activated Protein Kinase 3 (ERT2 or Insulin Stimulated MAP2 Kinase or Extracellular Signal Regulated Kinase 1 or MAP Kinase Isoform p44 or Microtubule Associated Protein 2 Kinase or p44 ERK1 or MAPK3 or EC 2.7.11.24)
- The report reviews Mitogen Activated Protein Kinase 3 (ERT2 or Insulin Stimulated MAP2 Kinase or Extracellular Signal Regulated Kinase 1 or MAP Kinase Isoform p44 or Microtubule Associated Protein 2 Kinase or p44 ERK1 or MAPK3 or EC 2.7.11.24) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in Mitogen Activated Protein Kinase 3 (ERT2 or Insulin Stimulated MAP2 Kinase or Extracellular Signal Regulated Kinase 1 or MAP Kinase Isoform p44 or Microtubule Associated Protein 2 Kinase or p44 ERK1 or MAPK3 or EC 2.7.11.24) targeted therapeutics and enlists all their major and minor projects
- The report assesses Mitogen Activated Protein Kinase 3 (ERT2 or Insulin Stimulated MAP2 Kinase or Extracellular Signal Regulated Kinase 1 or MAP Kinase Isoform p44 or Microtubule Associated Protein 2 Kinase or p44 ERK1 or MAPK3 or EC 2.7.11.24) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news and deals related to Mitogen Activated Protein Kinase 3 (ERT2 or Insulin Stimulated MAP2 Kinase or Extracellular Signal Regulated Kinase 1 or MAP Kinase Isoform p44 or Microtubule Associated Protein 2 Kinase or p44 ERK1 or MAPK3 or EC 2.7.11.24) targeted therapeutics
Reasons to buy
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand the targeted therapy areas and indications for Mitogen Activated Protein Kinase 3 (ERT2 or Insulin Stimulated MAP2 Kinase or Extracellular Signal Regulated Kinase 1 or MAP Kinase Isoform p44 or Microtubule Associated Protein 2 Kinase or p44 ERK1 or MAPK3 or EC 2.7.11.24)
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Mitogen Activated Protein Kinase 3 (ERT2 or Insulin Stimulated MAP2 Kinase or Extracellular Signal Regulated Kinase 1 or MAP Kinase Isoform p44 or Microtubule Associated Protein 2 Kinase or p44 ERK1 or MAPK3 or EC 2.7.11.24) development landscape
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Companies Mentioned
AGV Discovery SAS
Eli Lilly and Company
Kura Oncology Inc
Merck & Co Inc
Merck KGaA
